| Business Summary | | Cell
Therapeutics,
Inc.
acquires
and
commercializes
novel
treatments
for
cancer.
The
Company's
goal
is
to
build
a
leading,
vertically
integrated
biopharmaceutical
company
with
a
diversified
portfolio
of
proprietary
oncology
drugs.
The
Company's
research
and
in-licensing
activities
are
concentrated
on
identifying
new,
less
toxic
and
more
effective
ways
to
treat
cancer.
The
Company's
lead
product,
called
arsenic
trioxide,
or
TRISENOX,
received
FDA
approval
in
September
2000.
TRISENOX
is
initially
being
marketed
for
patients
with
a
type
of
blood
cell
cancer
called
Acute
Promyelocytic
Leukemia
(APL),
who
have
relapsed
or
failed
available
therapies.
In
its
pivotal
trial
in
patients
with
relapsed
or
refractory
APL,
70%
of
the
40
patients
experienced
complete
remission
following
treatment
with
TRISENOX,
with
78%
entering
a
molecular
remission. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cell
Therapeutics
is
a
biopharmaceutical
company
committed
to
making
cancer
a
treatable
disease
by
discovering,
developing
and
bringing
to
market
innovative
treatments
for
cancer.
For
the
six
months
ended
6/30/01,
revenue
totaled
$2.8
million,
vs.
$0.
Net
loss
applicable
to
Common
rose
20%
to
$27.7
million.
Results
reflect
initial
product
sales
for
Trisenox,
offset
by
higher
amortization
costs
due
to
the
acquisition
of
PolaRx,
and
marketing
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Max Link, Ph.D., 60 Chairman
of Directors, Director | -- | -- | James Bianco, M.D., 44 Pres,
CEO, Director | $742K | $6.6M | Louis Bianco, 48 Exec.
VP, Fin. and Admin. | 365K | 107K | Edward Kenney, 56 Exec.
VP, COO | 225K | -- | Jack Singer, M.D., 58 Exec.
VP, Research Program Chairman | 271K | 1.2M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|